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Introduction: This study was designed to determine the short-term
effect of acetyl-L-carnitine (ALC) on symptoms of withdrawal in opiate-
dependent subjects and animals and, in particular, on pain, given the
efficacy of ALC in other typologies of pain. The study consists of
2 branches: a clinical study and a preclinical one, both with a random-
ized placebo-controlled design.
Methods: Thirty subjects meeting clinical criteria for methadone
dependence were consecutively recruited and treated with ALC 2 g/d or
placebo for a 3-week detoxification period. Withdrawal symptoms and
pain were evaluated through the Short Opiate Withdrawal Syndrome
scale, and the Huskisson’s analogue scale for pain. In the preclinical
study, mice previously received a pretreatment (saline solution or
morphine), and subsequently, each group was randomly divided in 4
subgroups that received a treatment of saline, methadone, ALC, or
amitriptyline, respectively. Hot plate test and Writhing test were used to
evaluate pain intensity.
Results: Average Short Opiate Withdrawal Syndrome total scores
during the first 5 days of treatment resulted significantly higher in
controls than in the ALC group (P G 0.05). Pain scores in the Huskisson’s
analogue scale were considerably lower in the group of patients taking
ALC than in the control group after 1 week of ALC treatment until
the end of the study. Results of the preclinical study show that the
administration of methadone for 7 days in morphine-tolerant mice
did not produce any modification of the pain threshold. By contrast, the
7-day coadministration of methadone and ALC in morphine-tolerant
mice induced an analgesic effect evaluated 3 hours after the last
injection.
Discussion: Acetyl-L-carnitine acted as an effective antihyperalgesic
agent for relieving opiate-withdrawal hyperalgesia in animals and
displayed clinical efficacy on other withdrawal symptoms such as
muscular tension, muscular cramps, and insomnia. Considering its
tolerability, the excellent side effect profile, the absence of significant
interactions, and the lack of abuse potential, ALC can be considered as a
useful pharmacological adjunct in the treatment of opiate withdrawal.
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Opiate withdrawal, one of the longest studied and most well-described withdrawal syndromes, has been described as
akin to a moderate to severe flu-like illness.1 Pharmacological
treatments of opiate-withdrawal symptoms are designed to
smooth the progress of abstinence for a safe transition to a re-
lapse prevention program, through the improvement of signs and
symptoms.
Alpha-2 adrenergic agonist drugs are the main nonopiate
alternative for withdrawal, although the high rates of adverse
effects, including drowsiness, fatigue, lethargy, dry mouth, and
mainly hypotension, make this approach generally recom-
mended for a restricted number of patients.2
Among the characteristic withdrawal symptoms, pain,
together with insomnia, restlessness, and anxiety, was described
as the most resistant to treatment with clonidine,3 an alpha-2
adrenergic agonist regarded as an efficacious and safe treatment
both in outpatient and inpatient studies.4 Pain, often reported as
muscular aches, is considered as one of the most important
factors determining relapses or dropouts,5 therefore emphasiz-
ing the relevance of a possible strategy of treatment able to
reduce pain intensity, with a good side effect profile.
Different studies documenting the analgesic efficacy of
acetyl-L-carnitine (ALC) in neuropathic chronic pain have been
carried out. Acetyl-L-carnitine was efficacious and well tolerated
in improving neurophysiological parameters and reducing pain
during a 1-year period in patients with diabetic neuropathy, by
stimulating nerve regeneration and vibratory perception.6 In
HIV-positive patients affected by painful distal symmetrical
neuropathy7 and in HIV patients with established antiretroviral
toxic neuropathy after a long-term treatment8,9 ALC proved to
be an efficacious and safe alternative.
Moreover, the potential efficacy of ALC in the relief of
acute pain has been reported in animal models,10 postulating
an antinociceptive effect mediated by a central indirect cho-
linergic mechanism.11 Conversely, in the study of Vermeulen
and Scholte12 on patients with chronic fatigue syndrome, ALC
showed beneficial effects on mental fatigue and attention con-
centration but did not for pain complaints.
The study consists of 2 branches: a clinical study and
a preclinical one. The randomized, double-blind, placebo-
controlled clinical study was designed to determine the effect
of short-term ALC therapy on symptoms of withdrawal in
methadone-dependent subjects and, in particular, on pain,
given the efficacy of ALC in other typologies of pain. The effi-
cacy on the remaining acute withdrawal symptoms represented
a secondary objective: specifically, some withdrawal symptoms
such as insomnia, restlessness, and motor hyperactivity, could
be a target for ALC as postulated in other studies where ALC
resulted to be efficacious on similar symptoms in other psy-
chopathological frames such as insomnia in geriatric depres-
sion13 and restlessness and hyperactivity in attention deficit
hyperactivity disorder.14 Moreover, a preclinical study about
the use of ALC in the withdrawal syndromes15 showed the
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reduction of the onset of tremors in ethanol withdrawal as well
as the reduction of ethanol intake in alcohol-preferring rats
during treatment with ALC, thus providing further evidence
for the use of ALC in the clinical treatment of withdrawal
symptoms.
Because ALC was not administered as monotherapy in
dependent subjects, to clarify its actual effect, the ALC activity
on pain threshold was also tested in an animal model of meth-
adone dependence.
METHODS
Clinical Study
Subjects and Procedures
Thirty subjects meeting clinical criteria for methadone
dependence (Diagnostic and Statistical Manual of Mental
Disorder, Fourth Edition [DSM-IV]) were consecutively
recruited from the Day-Hospital of Psychiatry and Drug
Dependence of the University General Hospital BA. Gemelli[
in Rome (male-to-female ratio 4:1, mean age 32.8 T 6.2 years).
Patients, evaluated by attending psychiatrists through the
Structured Clinical Interview for DSM-IV and the European
version of Addiction Severity Index, were excluded from re-
cruitment if they had a severe physical illness and evidence of
mental disorders severely interfering with their cognitive
capacity or reality test (eg, a current or previous diagnosis of
schizophrenia, bipolar disorder, major depression, and any sub-
stance abuse or dependence [other than methadone dependence]
according to DSM-IV). Excluded from participation were sub-
jects regularly taking anticonvulsants, antidepressants, neuro-
leptics, or analgesics and subjects with chronic or ongoing acute
pain or with peripheral neuropathy, diabetes, and HIV.
Inclusion criteria were a daily methadone intake between
30 and 40 mg dating back at least 6 months, an age range
between 18 and 45 years, and Italian speaking. All the patients
recruited were effectively stabilized in treatment, defined as
having been on asteady and daily dosage of methadone (30 mg)
for at least 3 weeks, and were then randomized to receive ALC
or placebo. Participants were selected to match on age, race, and
gender. Only subjects volunteering to participate and providing
full informed consent were effectively recruited.
The structure of the study foresaw 3 weeks of treatment:
during the first week (T-7YT0), methadone was gradually re-
duced to 20 mg daily (orally) from the starting dosage (30 mg),
then methadone was abruptly suspended for the final 2 weeks of
study. For the first week of treatment, ALC (or placebo) was
given (2 g\d) orally, subdivided in 3 times daily, then intra-
venously at the same dosage for the remainder of the study
(T1YT14). During the study period, patients were only given
trazodone (100 mg\d) for the abstinence-related sympathetic
responses of tachycardia and hypertension, and given diazepam
(20 mg\d or equivalent) for insomnia according to established
and validated protocols.16 In case withdrawal symptoms se-
verely interfered with the patients’ clinical condition, patients
were adequately treated and considered as dropouts.
For the entire study period, patients attended (daily) a self-
help group based on a psychosocial program.
The following parameters were used (T7YT14) to determine
the efficacy of the medication: (1) the Short Opiate Withdrawal
Syndrome (SOWS)17 scale and (2) the Huskisson’s visual ana-
logue scale (VAS) for pain,18 both administered every day.
To evaluate the adverse event profile, physical assessment,
vital signs, and laboratory analyses were performed at T0, T4,
and T14.
The study was approved by the Institutional Review Boards
and the national regulatory authorities in accordance with local
requirements.
Statistical Analysis
Statistical analysis was performed using nonparametrical
tests.
Student t and chi-square tests were used to compare
sociodemographic and clinical data.
Chi-square was applied for the SOWS subscales and the
SOWS total score at different times (T0, T4, T9, T14) to verify a
possible association between the variables considered and the
treatment received. The Mann-Whitney U test was used to
analyze the differences between the group of subjects treated
with ALC and the control group, in terms of average scores in
the period of time between T0/T4, T5/T9, and T10/T14. The
average of the differences (DELTA) between T0/T4 and T5/T9,
T5/T9 and T10/T14, and T0/T4 and T10-T14 in both the ALC
and the control group were analyzed through the Friedman test
to verify a possible significant difference during the time course.
For the VAS scores, the Mann-Whitney U test was con-
ducted to identify differences between the 2 groups of subjects
at different times (T0, T4, T9, T14); for each group, DELTA
variables were calculated in all the intervals considered between
T0 and T14, and their differences were evidenced.
Finally, for the 2 groups separately, Friedman test was used
on the VAS score at different times (T7, T0, T4, T9, T14) to
verify the presence of a significant variation during the time
course considered.
Preclinical Study
Animals
Male Swiss albino mice (24Y26 g) from Morini (San Polo
d’Enza, Italy) were used. Fifteen mice were housed per cage.
The cages were placed in the experimental room 24 hours before
the test for acclimatization. The animals were fed a standard
laboratory diet and tap water ad libitum and kept at 23 T 1-C
with a 12-hour light/dark cycle, light at 7 AM. All experiments
were carried out in accordance with the National Institutes of
Health’s Guide for the Care and Use of Laboratory animals. All
efforts were made to minimize animal suffering and to reduce
the number of animals used.
Hot Plate Test
Mice were placed inside a stainless steel container that was
set thermostatically at 52.5 T 0.1-C in a precision water bath
from KW Mechanical Workshop, Siena, Italy. Reaction times
(seconds) were measured with a stopwatch before, 30 minutes
after and 7 days after treatments. The end point used was the
licking of the fore or hind paws. Those mice scoring less than 12
and more than 18 seconds in the pretest were rejected (30%). An
arbitrary cutoff time of 45 seconds was adopted.
Writhing Test
Mice were injected intraperitoneal with a 0.3% solution of
acetic acid (10 mL kgj1). The number of stretching movements
was counted for 10 minutes, starting 5 minutes after acetic acid
injection.
Administration Schedule
Animals received a pretreatment (saline or morphine) and
a treatment (saline, methadone, ALC, or amitriptyline). Mice
were randomly assigned to saline or morphine pretreatment
group. Pretreatment with morphine was conducted as follows:
10 mg kgj1 s.c. on day 1, 20 mg kgj1 s.c. on day 2, 40 mg kgj1
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s.c. on day 3, 50 mg kgj1 s.c. on day 4, 60 mg kgj1 s.c. on day
5, 70 mg kgj1 s.c. on day 6, and 80 mg kgj1 s.c. on day 7. After
pretreatment, each pretreated group was divided into 4 sub-
groups that received a treatment of saline, methadone, ALC, or
amitriptyline, respectively. Methadone was injected at the dose
of 10 mg kgj1 s.c. once daily for 7 days; ALC was administered
at the dose of 100 mg kgj1 i.p. twice daily for 7 days, whereas
amitriptyline was injected at the dose of 15 mg kgj1 s.c. twice
daily for 7 days. After pretreatment, each drug was coadminis-
tered with saline, and 2 groups were coadministered with
methadone and ALC, and methadone and amitriptyline,
respectively.
Statistical Analysis
Results from hot plate and writhing tests are given as the
mean T SEM; analysis of variance, followed by Fisher protected
least significant difference procedure for post hoc comparison,
was used to verify the significance between 2 means. P values of
less than 0.05 were considered significant. Data were analyzed
with the StatView for the Macintosh computer program.
RESULTS
Clinical Study
Among the 30 subjects recruited, 10 subjects did not
complete the treatment: 8 of them dropped out in the first week
of treatment (T7/T0), during the methadone reduction and
stabilization period, and 2 in the second week during the
withdrawal period, both of them receiving placebo. The 2 groups
of treated subjects (10 patients each) were not significantly
different in term of sex (ALC group male-to-female ratio 2.6:1;
controls 2.8/1), age (ALC group 31 T 3; controls 30 T 2.4),
employment condition, marital status, and level of education.
Pain scores in the Huskisson’s analogue scale were con-
siderably lower in the group of patients taking ALC than in
the control group both at T0 (P G 0.05), which means after
1 week of ALC treatment but before the methadone suspension,
T4 (P = 0.01) and T9 (P = 0.01) (Fig. 1). Moreover, the reduc-
tion of pain values normally observed after the first days of
acute withdrawal resulted to be significantly higher in the ALC
group than in placebo, considering the period T4/T14 (P = 0.01)
and particularly between T9/T14 (P G 0.01).
Average SOWS total scores during the first 5 days of
treatment were significantly higher in controls than in the ALC
group (P G 0.05).
Figure 2 shows the time course of the SOWS subscale for
pain; the average decreasing of intensity of this symptom be-
tween the first period of treatment (T0/T4) and the second (T5/
T9) was significantly higher in the ALC group with respect to
controls (P G 0.05).
The average decreasing of the SOWS subscale for muscular
tension was significantly higher in the ALC group with respect
to controls (P = 0.05), considering the first period of treatment
(T0/T4) toward the second (T5/T9).
With regard to muscular spasm intensity during the first
5 days of treatment, they resulted to be significantly higher in
controls (P G 0.05) than in the ALC group, whereas the average
decreasing of muscular spasm intensity between both the periods
of T0/T4 and the following of T5/T9 was higher in the ALC
group than controls (P = 0.05).
The symptoms of insomnia and feeling of coldness
significantly reduced in the ALC group (P G 0.005; P G 0.05)
during the entire study period, whereas they did not for the
control group; all the other withdrawal symptoms rated through
SOWS significantly reduced both in ALC and in control groups.
Stomach cramps and yawning were the only withdrawal
symptoms significantly more represented in the ALC group with
respect to controls (P G 0.05), at T0 and T14, respectively;
otherwise, these SOWS subscores did not significantly differ
between the 2 groups.
There were no adverse events during the study. No patients
showed craving for the drug; at discontinuation, we observed
no drug withdrawal syndrome or side effects due to drug
suspension.
Preclinical Study
Mice were pretreated with morphine once daily for 7 days.
On day 8, morphine pretreatment was stopped, and animals were
treated with methadone once daily for 7 days, from days 8 to 14.
The licking latency values in the hot plate test were recorded on
day 8 before starting the methadone treatment and 30 minutes
after methadone administration, evidencing the absence of any
modification of the pain threshold induced by methadone. By
contrast, in the control group, which received a pretreatment
with saline, methadone was able to induce antinociception
30 minutes after administration (Fig. 3).
The licking latency values were also recorded on day 14
after a 7-day treatment with methadone and, in particular,
3 hours after the last injection. No modification of the pain
threshold was observed in the morphine + methadone-treated
mice. In the saline + methadone-treated mice (control group),
the antinociceptive effect of methadone disappeared (Fig. 3).
In the same experimental conditions, the effect of treat-
ment with ALC was observed. In control animals, ALC did not
produce any effect 30 minutes after administration. Conversely,
administered twice daily for 7 days, ALC produced an increase
of the pain threshold. Similar results were obtained when ALC
was coadministered with methadone (Fig. 3).
FIGURE 1. Pain average scores in the Huskisson’s analogue scale
in ALC and control groups at different times.
FIGURE 2. SOWS subscale for pain in ALC and control groups at
different times from methadone suspension.
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The coadministration of ALC and methadone in morphine-
tolerant mice did not produce any modification of the licking
latency values before and 30 minutes after administration of
methadone. By contrast, after the 7-day treatment, an anti-
nociceptive effect was evidenced in the ALC-treated group
(Fig. 3).
By following the same administration schedule, the
effect produced by the coadministration of methadone and
FIGURE 3. Effect of ALC on methadone-dependent mice in the hot plate test. Animals were pretreated with saline or morphine for 7 days
(from days 1 to 7). Then animals received a treatment for further 7 days (from days 8 to 14) with saline, methadone, or ALC, as reported
below each column. Vertical lines represent SEM; *P G 0.05, in comparison with the licking latency value recorded before treatment.
FIGURE 4. Effect of amitriptyline onmethadone-dependentmice in the hot plate test. Animals were pretreatedwith saline or morphine for
7 days (from days 1 to 7). Then animals received a treatment for further 7 days (from days 8 to 14) with saline, methadone, or
amitriptyline, as reported below each column. Vertical lines represent SEM; *P G 0.05, in comparison with the licking latency value
recorded before treatment.
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amitriptyline was also evaluated in the hot plate test. In the
control group, amitriptyline produced antinociception, which
persisted after 7 days of repeated administration (Fig. 4).
Similarly, in the morphine-pretreated animals, amitriptyline
produced an increase of the pain threshold 30 minutes after
administration. By contrast, when coadministered with meth-
adone for 7 days, the antinociceptive effect completely dis-
appeared when detected 30 minutes after the last injection
(Fig. 4).
The effect produced by ALC in methadone-dependent
animals was also evaluated against a chemical, painful stimulus
by means of the writhing test. As reported in Figure 5, the
administration of methadone for 7 days in morphine-tolerant
mice did not produce any modification of the pain threshold. By
contrast, the 7-day coadministration of methadone and ALC in
morphine-tolerant mice induced an analgesic effect evaluated
3 hours after the last injection. Similar results were obtained in
the control group in which methadone and ALC were co-
administered for 7 days in mice that received saline as
pretreatment (Fig. 5).
CONCLUSIONS
The present results demonstrate that the withdrawal
symptom of pain can be blunted significantly using ALC,
which can be considered as a valid and effective option in the
management of pain during opiate-withdrawal syndromes.
The significant reduction of muscular tension and muscular
cramps in the ALC group may be interpreted by a direct effect of
ALC on muscular functioning, postulating ALC as an active
molecular group that represents an intermediate substrate usable
directly in the working tissue.19 However, muscular ache is the
most common type of pain presentation during opiate-
withdrawal syndrome; therefore, the reduced perception of
pain determined by ALC at this level could lead the patient to
underestimate symptoms coming from the muscular system.
In regard to insomnia, a secondary effect of ALC might be
hypothesized: the reduced pain intensity could account for
increased sleep duration and for a reduction of time required to
fall asleep. However, insomnia evaluated by a nonspecific
instrument such as SOWS, cannot be adequately assessed and
differentiated.
A limitation of the present study was that ALC was not
administered as monotherapy; consequently, it is difficult to un-
derstand the actual effect of ALC, although the low dosage of
trazodone used should not interfere with the typical development
of pain during withdrawal states, as described in different studies
showing the inefficacy of trazodone at dosage lower than 150 to
200 mg/d in different pain syndromes.20,21
Results obtained from preclinical studies further confirm
the antihyperalgesic activity of ALC. In methadone-dependent
mice, a 7-day cotreatment of methadone with ALC increased the
pain threshold against an acute thermal stimulus as well as
against a chemical stimulus. In these studies, mice received ALC
as monotherapy, suggesting that the effect on the pain threshold
observed is only related to ALC. It should be taken into account
that conversely to ALC, repeated administration of other
analgesic drugs, such as amitriptyline, on methadone-dependent
mice induced a complete loss of anticociceptive activity.
The lack of relevant side effects and the absence of abuse
liability make ALC a good alternative in the treatment of a
central symptom of opiate withdrawal such as pain together with
other antiwithdrawal drugs in a composite therapeutic program.
In summary, in this work, ALC acted as an effective
antihyperalgesic agent for relieving opiate-withdrawal hyper-
algesia in animals and displayed clinical efficacy on other with-
drawal symptoms such as muscular tension, muscular cramps,
and insomnia. Considering its tolerability, the excellent side
effect profile, the absence of significant interactions, and the lack
of abuse potential, ALC can be considered as a useful pharma-
cological adjunct in the treatment of opiate withdrawal and
deserves further research through other controlled studies with
larger samples of subjects.
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